BACTROBAN
LOE ApproachingNDATOPICALCREAM
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
BACTROBAN by GSK is clinical pharmacology pharmacokinetics following single or repeated intranasal applications of 0. First approved in 1997.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTROBAN is a topical antibiotic cream containing mupirocin, a small-molecule antibacterial agent produced by fermentation from Pseudomonas fluorescens. It works by inhibiting bacterial protein synthesis through reversible binding to bacterial isoleucyl-tRNA synthetase. The nasal formulation is indicated for nasal eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization as part of institutional infection control programs.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team size likely declining as brand prepares for generic erosion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following single or repeated intranasal applications of 0.2 gram of BACTROBAN NASAL 3 times daily for 3 days to 5 healthy adult male subjects, no evidence of systemic absorption of mupirocin was demonstrated. The dosage regimen used in this study was for…
Worked on BACTROBAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.